CRBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corbus Pharmaceuticals Holdings Inc (CRBP) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are mixed, with bearish moving averages and a neutral RSI. Options data shows extremely low put-call ratios, suggesting bullish sentiment, but the lack of recent news or significant catalysts diminishes the immediate appeal. Financial performance, while improving, remains negative, and the stock's trend suggests potential short-term declines. Analysts are optimistic about the long-term potential, but there are no immediate drivers for a strong entry point.
The MACD is below 0 and negatively contracting, indicating a bearish momentum. RSI is neutral at 60.846, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading near its pivot point of 9.05, with resistance at 9.821 and support at 8.278. Overall, the technical indicators do not suggest a strong buy signal.
The company reported encouraging results for '701 at ESMO in October and is awaiting regulatory feedback.
No recent news or significant trading trends from hedge funds or insiders. The stock trend analysis indicates a potential decline in the short term (-0.89% in the next day, -1.82% in the next week, -3.95% in the next month).
In Q4 2025, revenue remained at 0 with no growth. Net income improved to -20.55M, up 115.69% YoY, and EPS improved to -1.24, up 58.97% YoY. However, the company is still not profitable, and gross margin remains at 0.
Analyst sentiment is positive, with a raised price target and an Outperform rating. However, the catalysts mentioned are mid-2026 events, which do not align with the user's preference for immediate opportunities.
